MedTrace Logo

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

NCT01288963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2023-06-15

No results posted yet for this study

Summary

The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.

Conditions

  • Malignant Melanoma

Interventions

DRUG

IL-2

Observation only

Sponsors & Collaborators

Principal Investigators

  • David McDermott, MD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01288963 on ClinicalTrials.gov